Jane Street
NRIX icon

Jane Street’s Nurix Therapeutics NRIX Stock Holding History

Jane Street’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,200
Closed -$288K – 12544
2025
Q4 		$288K Buy
+15,200
New +$218K ﹤0.01% 8924

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Jane Street's NRIX Position: Q1 2026 in Review

Jane Street reduced its Nurix Therapeutics (NRIX) stake by 90% in Q1 2026, selling an estimated $1.78M and leaving 12,273 shares worth $190K. The position accounts for ﹤0.01% of the portfolio, ranked #10201.

Jane Street first reported a position in NRIX in Q4 2022 and has held it in 10 quarters since. The position peaked at $4.18M in Q2 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Jane Street held 12,273 shares of Nurix Therapeutics worth $190K as of Q1 2026.
  • Jane Street sold 107,131 Nurix Therapeutics shares in Q1 2026, an estimated $1.78M.
  • Nurix Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #10201 holding.
  • Jane Street first reported a position in Nurix Therapeutics in Q4 2022 and has held it in 10 quarters since.
  • Jane Street's Nurix Therapeutics position peaked at $4.18M in Q2 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.